Information Library
Results for: High-quality studies - Our Expertise
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
Quintiles Strengthens Late Phase Offerings with Acquisition of Outcome Sciences, Inc.
Press Release — October 19, 2011 – With late phase (Phase IIIB and Phase IV) research becoming increasingly important to multiple healthcare stakeholders, Quintiles has acquired Outcome Sciences, Inc. (Outcome).
-
Partnering is Key to Maximizing Rewards in Emerging Markets
Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.
-
Methods Matter
White Paper — July 18, 2011
As healthcare decision making becomes more complex, stakeholders are demanding real-world evidence tailored to their own individual needs. -
A Focus on CNS
Brochure — July 1, 2011
Quintiles is your ally for broad and deep CNS expertise in every aspect of the drug development process. -
Clinical Endpoint Committees
White Paper — February 22, 2011
As regulatory boards are expecting more from clinical endpoint committees, what guidance can you follow? This white paper sets forth current best practice for CECs. -
EXAMINING REAL-TIME DATA TO IMPROVE THE QUALITY AND EFFICIENCY OF DRUG DEVELOPMENT
Press Release — October 13, 2010 – White Paper authors explore how real-time data can enhance patient safety, strengthen quality and accelerate development timelines.
-
Is a REMS Request from FDA More Likely for Drugs & Biologics Indicated for Pediatric Use?
White Paper — October 8, 2010
Is a REMS Request From FDA More Likely For Drugs and Biologics Indicated for Pediatric Use? -
CRO Perspective
Presentation — July 7, 2010
Tom Grundstrom's presentation at DIA US 2010, CRO Perspective -
Accelerated Access
Case Study — June 2, 2010
Quintiles drew on extensive experience, a thorough understanding of the disease state and a myriad of tools in the Quintiles recruitment arsenal for a comprehensive solution to reach the right patients at the right time. -
Regulations for Clinical Studies in Pediatric Patients in the European Union
White Paper — March 10, 2010
After the United States issued pediatric drug study requirements, the European Union (EU) passed a regulation that created major changes to clinical studies for pediatric
